NYSEAMERICAN:APHB - Ampliphi Biosciences Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.89
▲ +0.23 (6.28%)

This chart shows the closing price for APHB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ampliphi Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APHB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APHB

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Ampliphi Biosciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $3.89.

This chart shows the closing price for APHB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Ampliphi Biosciences. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/26/2019HC WainwrightReiterated RatingBuy$3.50
11/9/2018HC WainwrightSet Price TargetBuy$4.00
10/19/2018HC WainwrightSet Price TargetBuy$4.00
8/10/2018HC WainwrightSet Price TargetBuy$6.00
6/7/2018HC WainwrightSet Price TargetBuy$6.00
5/16/2018HC WainwrightSet Price TargetBuy$6.00
3/15/2018HC WainwrightSet Price TargetBuy$6.00
1/17/2018HC WainwrightBoost Price TargetBuy ➝ Buy$5.00 ➝ $6.00
11/15/2017HC WainwrightSet Price TargetBuy$5.00
10/2/2017HC WainwrightSet Price TargetBuy$5.00
8/28/2017HC WainwrightReiterated RatingBuy
8/28/2017HC WainwrightInitiated CoverageBuy$5.00
(Data available from 7/1/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/3/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/1/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/3/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/1/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/1/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Ampliphi Biosciences logo
AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $3.89
Low: $3.89
High: $3.89

50 Day Range

MA: N/A

52 Week Range

Now: $3.89
Low: $0.15
High: $1.37

Volume

474 shs

Average Volume

842,200 shs

Market Capitalization

$130.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Ampliphi Biosciences?

The following Wall Street analysts have issued stock ratings on Ampliphi Biosciences in the last year:
View the latest analyst ratings for APHB.

What is the current price target for Ampliphi Biosciences?

0 Wall Street analysts have set twelve-month price targets for Ampliphi Biosciences in the last year.
View the latest price targets for APHB.

What is the current consensus analyst rating for Ampliphi Biosciences?

Ampliphi Biosciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for APHB.

How do I contact Ampliphi Biosciences' investor relations team?

Ampliphi Biosciences' physical mailing address is 3579 Valley Centre Drive, SAN DIEGO, CA 92130, United States. The biotechnology company's listed phone number is +1-804-8272524. The official website for Ampliphi Biosciences is www.ampliphibio.com. Learn More about contacing Ampliphi Biosciences investor relations.